• 24/7
  • Buzz
  • Startups
  • VC
  • Finance@
  • Work@
  • Innovation
  • Opinions
  • Search
  • cleanSearch
  • Accesabillty
  • calcalist logo
bycalcalist logo
  • Homepage
  • Tags search
  • Entera Bio

CTech 24/7

  • CyberArk, not SentinelOne, was always the goal, says Palo Alto CEO
  • Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”
  • CyberArk’s $25B exit enriches global funds, not Israelis
  • Check Point not for sale, says CEO as Palo Alto buys CyberArk for $25B
More stories in CTech

Entera Bio

3 stories about Entera Bio
  • Nasdaq. Photo: Nasdaq

    Fourth Time’s the Charm for Entera Bio IPO

    01.07.18|Dror ReichThe Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each

  • Pills (illustration)

    Entera Bio Files for Nasdaq IPO

    12.11.17|Lilach BaumerThe clinical stage company develops treatments mostly for osteoporosis and bone disorders

  • Orally administrated drugs

    IPO Hopeful Entera Bio Moves to Better Position

    13.09.17|Dror ReichClinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism

Load more
Ctech Logo
Twitter
Twitter
Facebook
Facebook
NewsLetter
Newsletter
Contact Us
Contact Us
Rss
Rss
About CTech Terms of Use Privacy Policy
Developed by YIT UI & UX by Basch_Interactive